Androgenic Alopecia TH07 Clinical Trial (MATT)

Phase III, Parallel Design, Triple-Blind, Randomized, Multicenter Clinical Trial to Evaluate Safety & Efficacy of TH07 Topical Treatment in Male Patients With Androgenic Alopecia.

The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.

Study Overview

• Status: Recruiting
• Conditions: Androgenic Alopecia
• Intervention / Treatment: Drug: TH07; Drug: TH07; Drug: Minoxidil 5% Topical Solution; Other: Placebo

Detailed Description

The MATT study is a Phase III clinical trial designed to evaluate the safety and effectiveness of a new topical hair growth treatment called TH07.

TH07 is a combined topical spray solution containing three active ingredients commonly used to treat hair loss: Minoxidil (5%) Finasteride (0.1%) and Latanoprost (0.03%). The study plans to enroll 420 men aged 18 to 49 years old across up to 10 clinical sites.

Participants will be randomly assigned to one of four groups to receive either TH07 (once or twice daily), a standard Minoxidil solution, or a placebo.

The treatment will be applied daily (once or twice) for 24 weeks.

• Study Type: Interventional
• Enrollment (Estimated): 420
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Edouard AL-Chami; Phone Number: 647-453-3253; Email: ealchami@triplehair.ca
• Study Contact Backup: Name: Lori Hebert; Email: lhebert@triplehair.ca

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V5Z1H2
      • Recruiting
      • YVR Aesthetic Training and Study Centre.
      • Contact: Janette Sen; Phone Number: 604-729-1911; Email: janette@yvrtrainingcentre.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Males, 18 to 49 years of age on the date of enrollment.
• Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale.
• Body Mass Index (BMI) in the range of 19 to 35 kg/m2.
• Not administered any systemic or topical treatment for AGA during the last 90 days.

• Willing to comply with the following restrictions for the duration of trial participation:

  1. Any systemic or topical treatment of any system of medicine (other than trial treatment) for AGA.
  2. Hair dyes, hair texturizers, relaxers etc.
  3. Any new vitamins or nutritional supplements that are currently not being administered.
  4. Tattooing in the trial target area.
  5. Blood donations.
  6. OTC hair restorers.
  7. Do not expose your pregnant partner to your hands/skin where the drug might be present.

  8. Participation in any other drug or device trials during the course of this trial.

     Note: However, the following shall be permissible:

  9. Non-medicated & anti-dandruff shampoos, scalp/hair applications including styling gels, sprays, mousse (styling gels, sprays, mousse etc. not to be used on the days of trial visits to the clinic.
  10. Current regimen (if any) of vitamins and nutritional supplements.
• Willing and able to provide written informed consent for participation in the trial and to comply with all trial requirements.
• Availability of and usage familiarity with a personal mobile phone (Android or iOS) with internet connectivity and a personal email address.

Exclusion Criteria:

• History of scalp treatment including though not limited to any of the following:

  1. Hair transplant or extension surgery.
  2. Hair weaving.
  3. Laser or light therapy on the scalp in the last 6 months.
  4. Micro-needling or intradermal therapy (mesotherapy) on the scalp including PRP in the last 6 months.

  5-Any other surgical treatment for hair loss

• Any of the following hair styles:

  1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.

• Known or presumed hypersensitivity to any trial treatment medication; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of investigator may affect the outcome of trial.
• Any other significant abnormalities indicating of severe, acute or chronic medical condition(s) that may lead to hair loss or otherwise interfere with the interpretation of trial results.
• History or likelihood of use of any of the specified medicines.
• History or clinical diagnosis of any of the specified medical conditions.
• Participation in any investigational or marketed drug or device trial in the last 90 days prior to screening for this trial.
• Any other condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A; All participants in Arm A will apply TH07 topical solution twice a day for 24 weeks	Drug: TH07; TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; twice a day; Drug: TH07; TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; once a day; Placebo; topical solution; once a day
Experimental: Arm B; All participants in Arm B will apply TH07 topical solution once a day and Placebo topical solution once a day for 24 weeks	Drug: TH07; TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; twice a day; Drug: TH07; TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; once a day; Placebo; topical solution; once a day
Active Comparator: Arm C; All participants in Arm C will apply Minoxidil 5% topical solution twice a day for 24 weeks	Drug: Minoxidil 5% Topical Solution; Minoxidil 5%; topical solution; twice a day
Placebo Comparator: Arm D; All participants in Arm D will apply Placebo topical solution twice a day for 24 weeks	Other: Placebo; Placebo; topical solution; twice a day

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Non-vellus hair count	Number of hair in the matched target area measured by phototrichogram	Baseline and week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hair diameter and cumulative hair thickness	hair thickness is defined as average hair diameter * hair count in the matched target area / size of matched target area (mm/cm2)	Baseline and week 24
Subject-reported improvement	self-assessment questionnaire	week 24
Non-vellus hair count	in the matched target area by phototrichogram between TH07 twice daily, TH07 once daily, and placebo	Baseline and week 24
Incidence of treatment related adverse events.	reporting of adverse events and serious adverse events	through study completion, average 28 weeks

Collaborators and Investigators

• Sponsor: Triple Hair Inc

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): April 1, 2028

Study Registration Dates

• First Submitted: February 18, 2026
• First Submitted That Met QC Criteria: February 24, 2026
• First Posted (Actual): February 27, 2026

Study Record Updates

• Last Update Posted (Actual): March 16, 2026
• Last Update Submitted That Met QC Criteria: March 12, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Hair Loss; Hair growth; Androgenic Alopecia; Balding
• Additional Relevant MeSH Terms: Pathological Conditions, Anatomical; Skin Diseases; Hypotrichosis; Hair Diseases; Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases; Alopecia; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pharmaceutical Preparations; Piperidines; Pyrimidines; Minoxidil; Solutions
• Other Study ID Numbers: TH0701

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No